regardless of promising clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial opposition from managed care entities. Such companies are typically creating limitations to reimbursement, such as high expense requirements and approval processes that hinder patien… Read More